BioNTech (NASDAQ: BNTX), the German drugmaker, has agreed to acquire Chinese biotech company Biotheus to support its oncology strategy and […]
BioNTech (NASDAQ: BNTX) Acquires China’s Biotheus to Support Oncology Strategy Read More »
On Monday, BioNTech (NASDAQ: BNTX), the German drugmaker, lowered its guidance for full-year revenue, citing COVID-19 uptake and price levels,
BioNTech Lowers 2024 Revenue Outlook on COVID-19 Seasonality and Inventory Write-downs Read More »
LONDON – On Tuesday, Pfizer (NYSE: PFE) and its German partner BioNTech (NASDAQ: BNTX) won their attempt to invalidate two
Pfizer and BioNTech Win Bid to Invalidate CureVac’s UK COVID Vaccine Patents Read More »
BERLIN – Losses at Germany’s BioNTech (NASDAQ: BNTX) quadrupled year-on-year in the second quarter, the company said on Monday, as
BioNTech (NASDAQ: BNTX) Q2 Losses Quadruple Amid Strategic Shift to Cancer Drugs Read More »
On Tuesday, BioNTech (NASDAQ: BNTX), the maker of the COVID-19 vaccine, said that its cancer drug candidate BNT111 significantly improved
BioNTech’s (NASDAQ: BNTX) Cancer Drug Meets Primary Endpoint in Phase 2 Trial Read More »
Copyright © 2024 abbonews.com
